Expanded access for a medicine for primary immunodeficiency
Part of Genetic & congenital, Immune system & allergy clinical trials.
This program lets people with primary immunodeficiency disease who were in an earlier study of this medicine continue receiving it if it is helping them. It is only for those who already took part in the earlier study and are still doing well on it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already completed the main study of this medicine (called TAK-881-3002).
- Your doctor must agree that you are still getting real benefit from the medicine.
- You must not be allergic to the medicine or any of its parts.
- If you could become pregnant, you must agree to use a highly effective birth control method during the program.
- You cannot be pregnant, breastfeeding, or planning to become pregnant during the program.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new antibody treatment called TAK-664 is safe and works for people with primary immunodeficiency who have never had antibody replacement before. It compares the new treatment to a standard approach, with the goal of helping prevent infections and improve quality of life.
This study looks at how well immunoglobulin replacement therapy works in people with low antibody levels and how it affects the immune system. It aims to help improve treatment for primary antibody immunodeficiencies.
This study is a safety check for people with primary immunodeficiency who are already using a specific immune globulin treatment given under the skin. It looks at medical records to see if any side effects occurred.
This study collects blood (and sometimes related samples) to learn how genes and the immune system work in people with primary immunodeficiency (PID) or in family members who may not have it. The goal is to improve understanding of rare immune conditions and help guide future care.
This program lets people with von Willebrand disease who finished a previous study keep getting the treatment if it worked well and there's no other good option. It continues care after the study ends.
This study tests a new investigational drug called TAK-411 for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). It is for people who have already responded to immunoglobulin therapy and are on a stable dose.
Hear when a new Primary Immunodeficiency Diseases (PIDD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.